Small, selective ROIs are less vulnerable to volume averaging, but may be skewed by fluctuations caused by Bortezomib spatial and temporal heterogeneity within the kidney, particularly in the medulla. Coronary atherosclerosis is the major cause of associated morbidity and mortality in the world. The critical coronary artery stenosis is a strong predictor for cardiovascular adverse events. Current perspectives regard thrombotic process and low grade chronic inflammation as critical contributors for plaque instability and stenosis progression. Identifying valuable and noninvasive markers is important for clinical decision-making in the treatment and prevention of coronary atherosclerosis. Fibrinogen is by far the most abundant coagulation factor in the blood. In addition to its essential properties as a cofactor of platelet aggregation and as part of the final common pathway of the coagulation cascade, fibrinogen is also a wellknown acute phase protein. During the last decades, several studies focused on fibrinogen and its relation to high risk of atherosclerotic diseases, most of which demonstrated that fibrinogen played a pivotal role in the initial phase and progressive stages of atherosclerosis. Multiple epidemiologic along with case-control studies revealed an association between the increased fibrinogen level and the early signs of atherosclerosis in asymptomatic individuals. The increased fibrinogen level has also been identified as an important risk factor for the future cardiovascular events in apparently healthy individuals and in patients with established coronary artery disease. Therefore, fibrinogen is proposed as a potential predictor for the risks of cardiovascular diseases. Although much positive evidence has been identified, more recent studies showed that fibrinogen could not provide additional information to that provided by traditional cardiovascular risk factors in predicting cardiovascular events. Additionally, according to fibrinogen genetic studies, polymorphisms which related to fibrinogen level were not associated with an increased cardiovascular risk. Therefore, the clinical significance of fibrinogen in the risk stratification for cardiovascular disease is still controversial. Besides, previous reports investigated the relation between fibrinogen and the severity of coronary atherosclerosis in patients with chronic CAD or acute coronary syndrome. Data enrolled patients with new-onset coronary atherosclerosis quantitatively by coronary angiography and Gensini score system were obscure. Moreover, large-scale studies were currently unavailable regarding subjects representative of Han Chinese population. Therefore, the aim of the current study was to investigate the association of plasma fibrinogen level with the presence and severity of new-onset coronary atherosclerosis assessed by GS in a large cohort of Han Chinese population. To the best of our knowledge, this is the first study evaluated the relationship of plasma fibrinogen level with the presence and severity of new-onset coronary atherosclerosis assessed by GS system in a large cohort of Han Chinese population.